2023 NPC Winter Webinar: Emerging Uses of AI in the Life Sciences
The 2023 NPC Winter Webinar is taking place tomorrow (Wed. April 19) at 11 am EDT. Here's a taste of what you'll hear in tomorrow’s session (720 words, 3 minutes)
NPC Healthbiz Weekly is presented to you with support from Impres, Canada’s Next Generation Commercial Partner
Artificial intelligence (AI) has taken the world by storm, and the life sciences industry is in the middle of this disruption. From automatized chatbots in pharma websites to surgical devices that assist surgeons during complex procedures, AI is slowly making its way into almost every aspect of the healthcare industry.
The 2023 NPC Winter Webinar, taking place tomorrow, will examine the emerging uses of AI in the life sciences. The event will feature a panel of experts discussing the latest developments in this rapidly evolving field.
The panel includes Dr. Jaggi Rao of the University of Alberta in Edmonton, Patrick Massad of the Pharmaceutical Advertising Advisory Board (PAAB), and Anastasia Lit of the Dubai-based health tech consultancy TechPharus. They will provide insights regarding the benefits and challenges of integrating AI technologies into the industry and how AI is changing how drugs are developed, tested, and delivered to patients.
Drug discovery is one of the main areas of the life sciences industry where AI has a significant impact. According to guest speaker Anastasia Lit, AI speeds up the process by identifying potential drug candidates more efficiently and accurately. This process, which used to take up to 12 years, may now only take two to three years, permitting pharma companies to bring new drugs to market faster.
Personalized medicine also shows great promise when it comes to AI implementation. AI algorithms can analyze patient data to help identify the most effective treatments for patients based on their specific genetic and medical profiles. At the same time, AI can help identify patients most likely to benefit from a particular treatment and can help monitor their responses to these treatments.
So, join your colleagues and friends tomorrow at 11 a.m. EST to learn more about the latest developments in AI. The session will be one hour long, and registration is free. Space is limited, so sign up today using this link.
THIS WEEK 04/11/23
Horizon Therapeutics announced the U.S. FDA has approved an update to the Indications and Usage section of the teprotumumab-trbw (Tepezza) label to specify its use for the treatment of “Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.” The Government of Canada is investing close to $164 million to support home and community care, mental health, and addiction services in British Columbia.
Health Canada accepted Pfizer’s New Drug Submission for its bivalent Respiratory Syncytial Virus (RSV) vaccine for review. The vaccine is currently being reviewed to prevent lower respiratory tract disease and severe respiratory tract disease caused by RSV.
Filament Health Corp. and PharmAla Biotech Holdings Inc. announced the GMP release of MDMA capsules at the Metro Vancouver facility operated by Filament’s subsidiary Psilo Scientific.
LISTEN NOW
In season nine of the NPC Podcast, Anastasia Lit, Co-founder of TechPharus, talks about using AI to enhance medical care and research, the rapid development of software and AI technologies, and how AI is transforming the labour market. Hear her in conversation with podcast hosts Mitch Shannon, Jim Shea and Mark McElwain.
HEALTHBIZ REWIND
This new feature of NPC Healthbiz Weekly looks back at some of the most insightful moments from previous NPC Podcast episodes. In Healthbiz Rewind, you’ll read bold life sci predictions made during the popular Prognostication Korner segment of the NPC Podcast.
Anastasia Lit
Dubai
TechPharus
Season 9, episode 08
Listen to this episode here
What bold predictions will you make about the life sciences industry during the coming 12 to 24 months?
We’ve seen the development of Open AI. Many companies have worked on chatbots and virtual assistants for the past decade. It wasn’t until 2023 that we got ChatGPT, and we can use the app and not spend time developing chatbots. The same [significant developments] will happen in the life sciences industry.
We can expect many advancements, such as nanotechnology, surgical robots, and virtual clinics. We can expect more cooperation between big tech and life science companies as time progresses. We already see the strategic alliances and that the big tech companies can become big tech life-sciences companies in the future.
Register now for the upcoming NPC Webinar
The 2023 NPC Webinar will explore the rapidly evolving field of artificial intelligence (AI) in the life sciences industry. The webinar will bring together a panel of industry leaders to discuss the emerging applications of AI in areas such as drug discovery, clinical trials, personalized medicine, and healthcare delivery.
Speakers Dr. Jaggi Rao of the University of Alberta, Patrick Massad of PAAB, and Anastasia Lit of TechPharus, share their perspectives on the benefits and challenges of implementing AI technologies and how they transform how drugs are developed, tested, and delivered to patients.
The webinar will be held virtually starting at 11:00 a.m. on Wednesday, April 19, 2023, will be one hour long, and is free to attend. Space is limited, so sign up today.
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly, and we’ll send each issue to your phone or inbox each Tuesday at 6:00 a.m. sharp.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 555 Burnhamthorpe Road Suite 306, Toronto, Ont. M9C 2Y3 T 416 916 2476
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Kylie Rebernik, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development
Content is copyright (c) 2023, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Subscribe for free to receive new posts directly to your inbox.